Dr. Sandy Srinivas

Dr. Srinivas is Professor of Medicine (Oncology) at Stanford University and, by courtesy, of Urology. She directs the Genitourinary Oncology Clinical Research Group, overseeing interventional trials that evaluate androgen-receptor blockade, PARP inhibition, and novel radioligand therapies across prostate, bladder, and renal cancers. Her leadership extends to medical directorship of Stanford’s inpatient hematology–oncology unit, where she develops quality-improvement pathways that reduce therapy-related complications.

 

Her translational collaborations explore biomarkers of treatment resistance and immune-checkpoint response. Recent work as co-investigator on KEYNOTE-564 demonstrated survival benefits of adjuvant pembrolizumab in high-risk renal-cell carcinoma, influencing FDA approval and current NCCN guidelines. Concurrent projects test PSMA-targeted radiopharmaceuticals and dual-pathway blockade in metastatic castration-resistant prostate cancer, guided by liquid-biopsy genomic profiling.

 

Nationally, Dr. Srinivas serves as vice-chair of the NCCN Prostate Cancer Panel, crafting consensus algorithms adopted worldwide (https://education.nccn.org/node/94837). She reviews grants for the Department of Defense Prostate Cancer Research Program and lectures internationally on integrating imaging with systemic therapy. Her commitment to mentorship is reflected in multiple Stanford Oncology Fellows Teaching Awards and the Denise O’Leary Clinical Excellence Award from Stanford Hospital’s Board of Directors.